Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) had its price objective reduced by investment analysts at Piper Sandler from $46.00 to $43.00 in a research note issued to investors on Wednesday, FlyOnTheWall reports. Piper Sandler’s price objective would suggest a potential upside of 43.33% from the company’s current price.
Other equities analysts also recently issued reports about the stock. StockNews.com assumed coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, May 18th. They set a “buy” rating on the stock. TheStreet lowered shares of Supernus Pharmaceuticals from a “b+” rating to a “c+” rating in a report on Friday, May 12th.
Supernus Pharmaceuticals Trading Down 0.9 %
NASDAQ SUPN traded down $0.28 on Wednesday, hitting $30.00. 64,889 shares of the stock traded hands, compared to its average volume of 428,059. The company has a market capitalization of $1.63 billion, a P/E ratio of 33.76 and a beta of 0.99. The stock has a 50-day moving average of $32.36 and a 200 day moving average of $35.94. Supernus Pharmaceuticals has a twelve month low of $29.06 and a twelve month high of $42.09.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.17. The business had revenue of $153.80 million during the quarter, compared to analyst estimates of $139.02 million. Supernus Pharmaceuticals had a return on equity of 5.96% and a net margin of 7.79%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 EPS. As a group, equities research analysts expect that Supernus Pharmaceuticals will post 1.21 earnings per share for the current year.
Hedge Funds Weigh In On Supernus Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. Glass Jacobson Investment Advisors llc bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth about $36,000. Cerity Partners LLC purchased a new stake in Supernus Pharmaceuticals during the 1st quarter valued at $431,000. Public Employees Retirement System of Ohio lifted its position in shares of Supernus Pharmaceuticals by 41.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 368 shares during the period. Tower Research Capital LLC TRC lifted its position in Supernus Pharmaceuticals by 389.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,056 shares during the period. Finally, Mendota Financial Group LLC bought a new stake in Supernus Pharmaceuticals during the 1st quarter valued at about $46,000.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.